Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.04 | N/A | -1.66% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.04 | N/A | -1.66% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautious optimism about future projects. They are focused on improving their product pipeline and operational strategies.
Management highlighted ongoing efforts to enhance product development.
They emphasized the importance of upcoming clinical trials.
There was a focus on maintaining operational efficiency.
Despite missing EPS expectations, Kodiak Sciences' stock rose by 13.25% following the earnings report. The increase may be attributed to positive management commentary regarding future product development and operational improvements. Investors seem to be reacting favorably to the potential growth opportunities outlined by the company.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NIKE INC Class B
Mar 31, 2026